First Line Metastatic Breast Cancer Treatment (ESMERALDA)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase
III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra
toxicities.
It could be interesting to explore the combination of bev + eribulin in first line metastatic
breast cancer.